Fig. 5From: Triplet‐drug chemotherapy combined with anti‐EGFR antibody as an effective therapy for patients with initially unresectable metastatic colorectal cancer: a meta-analysisForest plots. The reported grades 3 or 4 adverse event rates in patients who received FOLFOXIRI + anti-EGFR antibody or FOLFOXIRI (A diarrhea. B Neutropenia)Back to article page